|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Strobl JS, Kirkwood KL, Lantz TK, Lewine
MA, Peterson VA and Worley JF III: Inhibition of human breast
cancer cell proliferation in tissue culture by the neuroleptic
agents pimozide and thioridazine. Cancer Res. 50:5399–5405.
1990.PubMed/NCBI
|
|
5
|
Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M,
Zeldich E and Weizman A: Characterization of phenothiazine-induced
apoptosis in neuroblastoma and glioma cell lines: clinical
relevance and possible application for brain-derived tumors. J Mol
Neurosci. 22:189–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhelev Z, Ohba H, Bakalova R, Hadjimitova
V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress
proliferation and induce apoptosis in cultured leukemic cells
without any influence on the viability of normal lymphocytes.
Phenothiazines and leukemia. Cancer Chemother Pharmacol.
53:267–275. 2004. View Article : Google Scholar
|
|
7
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer
cells. Gynecol Oncol. 120:121–127. 2011.PubMed/NCBI
|
|
8
|
Byun HJ, Lee JH, Kim BR, Kang S, Dong SM,
Park MS, Lee SH, Park SH and Rho SB: Anti-angiogenic effects of
thioridazine involving the FAK-mTOR pathway. Microvasc Res.
84:227–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramu A, Spanier R, Rahamimoff H and Fuks
Z: Restoration of doxorubicin responsiveness in
doxorubicin-resistant P388 murine leukaemia cells. Br J Cancer.
50:501–507. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akiyama S, Shiraishi N, Kuratomi Y,
Nakagawa M and Kuwano M: Circumvention of multiple-drug resistance
in human cancer cells by thioridazine, trifluoperazine, and
chlorpromazine. J Natl Cancer Inst. 76:839–844. 1986.PubMed/NCBI
|
|
11
|
Castaing M, Loiseau A and Cornish-Bowden
A: Synergy between verapamil and other multidrug-resistance
modulators in model membranes. J Biosci. 32:737–746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kamiwatari M, Nagata Y, Kikuchi H,
Yoshimura A, Sumizawa T, Shudo N, Sakoda R, Seto K and Akiyama S:
Correlation between reversing of multidrug resistance and
inhibiting of [3H]azidopine photolabeling of
P-glycoprotein by newly synthesized dihydropyridine analogues in a
human cell line. Cancer Res. 49:3190–3195. 1989.
|
|
13
|
Spengler G, Molnar J, Viveiros M and
Amaral L: Thioridazine induces apoptosis of multidrug-resistant
mouse lymphoma cells transfected with the human ABCB1 and inhibits
the expression of P-glycoprotein. Anticancer Res. 31:4201–4205.
2011.PubMed/NCBI
|
|
14
|
Sachlos E, Risueno RM, Laronde S, et al:
Identification of drugs including a dopamine receptor antagonist
that selectively target cancer stem cells. Cell. 149:1284–1297.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gil-Ad I, Shtaif B, Levkovitz Y,
Nordenberg J, Taler M, Korov I and Weizman A: Phenothiazines induce
apoptosis in a B16 mouse melanoma cell line and attenuate in
vivo melanoma tumor growth. Oncol Rep. 15:107–112.
2006.PubMed/NCBI
|
|
16
|
Efferth T and Volm M: Reversal of
doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of
different resistance mechanisms. Cancer Lett. 70:197–202. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sutton LP and Rushlow WJ: The dopamine D2
receptor regulates Akt and GSK-3 via Dvl-3. Int J
Neuropsychopharmacol. 15:965–979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dubrovska A, Kim S, Salamone RJ, Walker
JR, Maira SM, Garcia-Echeverria C, Schultz PG and Reddy VA: The
role of PTEN/Akt/PI3K signaling in the maintenance and viability of
prostate cancer stem-like cell populations. Proc Natl Acad Sci USA.
106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gabalec F, Beranek M, Netuka D, Masopust
V, Nahlovsky J, Cesak T, Marek J and Cap J: Dopamine 2 receptor
expression in various pathological types of clinically
non-functioning pituitary adenomas. Pituitary. 15:222–226. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gatto F and Hofland LJ: The role of
somatostatin and dopamine D2 receptors in endocrine tumors. Endocr
Relat Cancer. 18:R233–R251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu HN, Huang WD, Cai Y, et al:
HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for
liver cancer as a cancer targeting gene-viro-therapy strategy. Mol
Cancer. 10:1332011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding M, Cao X, Xu HN, et al: Prostate
cancer-specific and potent antitumor effect of a
DD3-controlled oncolytic virus harboring the PTEN
gene. PLoS One. 7:e351532012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sheikhpour M, Ahangari G, Sadeghizadeh M
and Deezagi A: A novel report of apoptosis in human lung carcinoma
cells using selective agonist of D2-like dopamine receptors: a new
approach for the treatment of human non-small cell lung cancer. Int
J Immunopathol Pharmacol. 26:393–402. 2013.PubMed/NCBI
|
|
25
|
Senogles SE: D2 dopamine receptor-mediated
antiproliferation in a small cell lung cancer cell line, NCI-H69.
Anticancer Drugs. 18:801–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
